# Sotera Health Co: overview

SHC · Nasdaq · CIK 1822479 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/shc.md) · [Financials](/companies/shc/financials.md) · [Filings](/companies/shc/filings.md) · [Insiders](/companies/shc/insiders.md)

Latest reported revenue: [$321.4m](/filings/0001822479-26-000047.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001822479-26-000047).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [285](/filings/0001822479-25-000054.md) | [290 d](/filings/0001822479-26-000015.md) | [255](/filings/0001822479-26-000031.md) | [294](/filings/0001822479-26-000047.md) | [311](/filings/0001822479-25-000054.md) | [303 d](/filings/0001822479-26-000015.md) | [280](/filings/0001822479-26-000031.md) | [321](/filings/0001822479-26-000047.md) |
| Gross margin | % | [55.4%](/filings/0001822479-25-000054.md) | [56.6% d](/filings/0001822479-26-000015.md) | [53.2%](/filings/0001822479-26-000031.md) | [56.6%](/filings/0001822479-26-000047.md) | [57.0%](/filings/0001822479-25-000054.md) | [54.7% d](/filings/0001822479-26-000015.md) | [52.5%](/filings/0001822479-26-000031.md) | [55.4%](/filings/0001822479-26-000047.md) |
| Operating margin | % | [28.2%](/filings/0001822479-24-000049.md) | [30.0% d](/filings/0001822479-25-000015.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [6.0%](/filings/0001822479-25-000054.md) | [4.2% d](/filings/0001822479-26-000015.md) | [(5.2%)](/filings/0001822479-26-000031.md) | [2.7%](/filings/0001822479-26-000047.md) | [15.5%](/filings/0001822479-25-000054.md) | [11.5% d](/filings/0001822479-26-000015.md) | [9.5%](/filings/0001822479-26-000031.md) | [16.7%](/filings/0001822479-26-000047.md) |
| Diluted EPS | $ per share | [0.06](/filings/0001822479-25-000054.md) | not reported | [(0.05)](/filings/0001822479-26-000031.md) | [0.03](/filings/0001822479-26-000047.md) | [0.17](/filings/0001822479-25-000054.md) | not reported | [0.09](/filings/0001822479-26-000031.md) | [0.19](/filings/0001822479-26-000047.md) |
| Free cash flow | $m | [61.1 d](/filings/0001822479-25-000054.md) | [(10.2) d](/filings/0001822479-26-000015.md) | [35.6](/filings/0001822479-26-000031.md) | [26.2 d](/filings/0001822479-26-000047.md) | [35.0 d](/filings/0001822479-25-000054.md) | [52.4 d](/filings/0001822479-26-000015.md) | [(16.7)](/filings/0001822479-26-000031.md) | [42.0 d](/filings/0001822479-26-000047.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [931](/filings/0001822479-24-000011.md) | [1,004](/filings/0001822479-25-000015.md) | [1,049](/filings/0001822479-26-000015.md) | [1,100](/filings/0001822479-26-000015.md) | [1,164](/filings/0001822479-26-000015.md) |
| Gross margin | % | [55.7%](/filings/0001822479-24-000011.md) | [55.5%](/filings/0001822479-25-000015.md) | [55.0%](/filings/0001822479-26-000015.md) | [54.7%](/filings/0001822479-26-000015.md) | [55.5%](/filings/0001822479-26-000015.md) |
| Operating margin | % | [27.6%](/filings/0001822479-24-000011.md) | [24.7%](/filings/0001822479-25-000015.md) | [26.4%](/filings/0001822479-25-000015.md) | [27.0%](/filings/0001822479-25-000015.md) | not reported |
| Net margin | % | [12.5%](/filings/0001822479-24-000011.md) | [(23.3%)](/filings/0001822479-25-000015.md) | [4.9%](/filings/0001822479-26-000015.md) | [4.0%](/filings/0001822479-26-000015.md) | [6.7%](/filings/0001822479-26-000015.md) |
| Diluted EPS | $ per share | [0.41](/filings/0001822479-24-000011.md) | [(0.83)](/filings/0001822479-25-000015.md) | [0.18](/filings/0001822479-26-000015.md) | [0.16](/filings/0001822479-26-000015.md) | [0.27](/filings/0001822479-26-000015.md) |
| Free cash flow | $m | [179](/filings/0001822479-24-000011.md) | [95.6](/filings/0001822479-25-000015.md) | [(363)](/filings/0001822479-26-000015.md) | [45.1](/filings/0001822479-26-000015.md) | [149](/filings/0001822479-26-000015.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/shc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Sessa Capital IM, L.P.](/funds/1595849.md) | 2026-06-30 | $480.1m | 27,050,000 |  | Added +4,000,000 |
| [Darsana Capital Partners LP](/funds/1609098.md) | 2026-06-30 | $479.3m | 27,000,000 |  | Added +1,000,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $428.6m | 24,148,424 |  | Added +3,298,845 |
| [Sculptor Capital LP](/funds/1054587.md) | 2026-06-30 | $426.0m | 24,000,000 |  | Added +2,282,272 |
| [Sachem Head Capital Management LP](/funds/1582090.md) | 2026-06-30 | $276.2m | 15,560,000 |  | Added +3,915,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $216.0m | 12,170,699 |  | Added +1,435,693 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $212.0m | 11,946,341 |  | Added +1,337,624 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $186.4m | 10,734,313 |  | Added +4,013,550 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $149.1m | 8,402,106 |  | Not compared |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $147.8m | 8,324,321 |  | Added +1,302,695 |

## Recent filings

[All 379 filings](/companies/shc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-14 | 11:17 ET | [8-K](/filings/0001822479-26-000050.md) | 5.02 Departure or appointment of officers or directors | 0001822479-26-000050 |
| 2026-08-06 | 20:04 ET | [10-Q](/filings/0001822479-26-000047.md) | Quarterly report, period 2026-06-30 | 0001822479-26-000047 |
| 2026-08-06 | 11:19 ET | [8-K](/filings/0001822479-26-000044.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001822479-26-000044 |
| 2026-05-22 | 20:09 ET | [8-K](/filings/0001822479-26-000034.md) | 5.07 Shareholder vote results | 0001822479-26-000034 |
| 2026-05-20 | 20:10 ET | [8-K](/filings/0001193125-26-232585.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-232585 |
| 2026-05-13 | 20:11 ET | [8-K](/filings/0001193125-26-221630.md) | 1.02 Termination of a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-221630 |
| 2026-05-05 | 20:19 ET | [10-Q](/filings/0001822479-26-000031.md) | Quarterly report, period 2026-03-31 | 0001822479-26-000031 |
| 2026-05-05 | 11:13 ET | [8-K](/filings/0001822479-26-000028.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001822479-26-000028 |
| 2026-04-08 | 20:30 ET | [DEF 14A](/filings/0001104659-26-040937.md) | Proxy statement, period 2026-05-21 | 0001104659-26-040937 |
| 2026-03-16 | 11:14 ET | [8-K](/filings/0001822479-26-000019.md) | 5.02 Departure or appointment of officers or directors | 0001822479-26-000019 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001822479-26-000015.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/55e8ae0b-30b4-432b-a93a-616ac5b9fbc2)

## About the filer

- CIK: 1822479
- Tickers: SHC
- Exchange: Nasdaq
- SIC code: 8090 Services-Misc Health & Allied Services, NEC
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.